All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert-v1

X

Find FDA Investigational New Drug (IND) Submissions for Musculoskeletal

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

Country

News Type

Company

Product Type

Deal Size

refresh

Product Type

Companies

Cadent Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Pharma Nanotech & Nanomedicine

Participation Not Confirmed

Request a Meeting Now

Cadent Therapeutics Announces FDA Acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)

Contact the Supplier

Lead Product(s): Cad-1883

Therapeutic Area: Musculoskeletal

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

The Phase 2 trial is a multicenter, randomized, placebo-controlled study that will evaluate the safety and efficacy of CAD-1883. Efficacy outcome measures.